Orphanet: Búsqueda simple

ESTADOS UNIDOS

Washington
ADDRESS: NOT PROVIDED - US

EVADE: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa - AT
Institution: Information not provided - US

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

CD-ON-CAT8015-1036 - A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin - UK
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

Estudio de fase 2, multicéntrico y de un solo brazo de moxetumomab pasudotox en pacientes pediátricos con leucemia linfoblástica aguda infantil o linfoma linfoblástico B refractarios o en recidiva (completado)
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

Ensayo pivotal multicéntrico de moxetumomab pasudotox en la leucemia de células pilosas recidivante/resistente (Fase III) (completado)
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

CD-IA-MEDI-551-1155: A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (Phase II/III) - DE
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - SE
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

Estudio de seguridad, tolerabilidad y actividad clínica de MEDI4736 y tremelimumab administrados en monoterapia y en combinación a pacientes con carcinoma hepatocelular no resecable - ES
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

Ensayo de fase 2, aleatorizado y con doble enmascaramiento, de comparación entre tremelimumab y placebo en el tratamiento de segunda o tercera línea de pacientes con mesotelioma pleural o peritoneal maligno e irresecable (completado)
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)- BE (completed)
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - BE
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - FR
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - DE
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) - FR
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - FR
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - GB
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma - GB
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - GB
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL -DE-
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma -Prematurely Ended- -DE-
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma -GB
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders-CA
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

Estudio con doble enmascaramiento, controlado con placebo, con un período abierto para evaluar la eficacia y seguridad de MEDI-551 en sujetos adultos con neuromielitis óptica y trastornos del espectro de la neuromielitis óptica (Fase II-III)
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma - IT
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult (EE)
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

EVADE: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa
MedImmune, LLC

Para más detalles

PAISES BAJOS (LOS)

Utrecht
ADDRESS: NOT PROVIDED - NL

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Institution: Information not provided - NL

Para más detalles

Búsqueda de un ensayo clínico

Otra(s) opcion(es) de búsqueda

36 Resultado(s)

Ensayo(s) clínico(s) nacional(es)

EVADE: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa - AT Institution: Information not provided - US

CD-ON-CAT8015-1036 - A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin - UK MedImmune, LLC

Estudio de fase 2, multicéntrico y de un solo brazo de moxetumomab pasudotox en pacientes pediátricos con leucemia linfoblástica aguda infantil o linfoma linfoblástico B refractarios o en recidiva (completado) MedImmune, LLC

Ensayo pivotal multicéntrico de moxetumomab pasudotox en la leucemia de células pilosas recidivante/resistente (Fase III) (completado) MedImmune, LLC

CD-IA-MEDI-551-1155: A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (Phase II/III) - DE MedImmune, LLC

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - SE MedImmune, LLC

Estudio de seguridad, tolerabilidad y actividad clínica de MEDI4736 y tremelimumab administrados en monoterapia y en combinación a pacientes con carcinoma hepatocelular no resecable - ES MedImmune, LLC

Ensayo de fase 2, aleatorizado y con doble enmascaramiento, de comparación entre tremelimumab y placebo en el tratamiento de segunda o tercera línea de pacientes con mesotelioma pleural o peritoneal maligno e irresecable (completado) MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)- BE (completed) MedImmune, LLC

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - BE MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - FR MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - DE MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) - FR MedImmune, LLC

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - FR MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - GB MedImmune, LLC

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma - GB MedImmune, LLC

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - GB MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL -DE- MedImmune, LLC

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma -Prematurely Ended- -DE- MedImmune, LLC

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma -GB MedImmune, LLC

A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders-CA MedImmune, LLC

Estudio con doble enmascaramiento, controlado con placebo, con un período abierto para evaluar la eficacia y seguridad de MEDI-551 en sujetos adultos con neuromielitis óptica y trastornos del espectro de la neuromielitis óptica (Fase II-III) MedImmune, LLC

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma - IT MedImmune, LLC

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult (EE) MedImmune, LLC

Ensayo(s) clínico(s) multinacional(es)

A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin MedImmune, LLC

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents MedImmune, LLC

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis MedImmune, LLC

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma MedImmune, LLC

A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL MedImmune, LLC

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma MedImmune, LLC

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma MedImmune, LLC

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders MedImmune, LLC

EVADE: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa MedImmune, LLC

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Institution: Information not provided - NL

EVADE: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa - AT
Institution: Information not provided - US

CD-ON-CAT8015-1036 - A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin - UK
MedImmune, LLC

Estudio de fase 2, multicéntrico y de un solo brazo de moxetumomab pasudotox en pacientes pediátricos con leucemia linfoblástica aguda infantil o linfoma linfoblástico B refractarios o en recidiva (completado)
MedImmune, LLC

Ensayo pivotal multicéntrico de moxetumomab pasudotox en la leucemia de células pilosas recidivante/resistente (Fase III) (completado)
MedImmune, LLC

CD-IA-MEDI-551-1155: A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (Phase II/III) - DE
MedImmune, LLC

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - SE
MedImmune, LLC

Estudio de seguridad, tolerabilidad y actividad clínica de MEDI4736 y tremelimumab administrados en monoterapia y en combinación a pacientes con carcinoma hepatocelular no resecable - ES
MedImmune, LLC

Ensayo de fase 2, aleatorizado y con doble enmascaramiento, de comparación entre tremelimumab y placebo en el tratamiento de segunda o tercera línea de pacientes con mesotelioma pleural o peritoneal maligno e irresecable (completado)
MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)- BE (completed)
MedImmune, LLC

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - BE
MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - FR
MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - DE
MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) - FR
MedImmune, LLC

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - FR
MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents - GB
MedImmune, LLC

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma - GB
MedImmune, LLC

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - GB
MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL -DE-
MedImmune, LLC

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma -Prematurely Ended- -DE-
MedImmune, LLC

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma -GB
MedImmune, LLC

A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders-CA
MedImmune, LLC

Estudio con doble enmascaramiento, controlado con placebo, con un período abierto para evaluar la eficacia y seguridad de MEDI-551 en sujetos adultos con neuromielitis óptica y trastornos del espectro de la neuromielitis óptica (Fase II-III)
MedImmune, LLC

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Subjects With Advanced Hepatocellular Carcinoma - IT
MedImmune, LLC

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult (EE)
MedImmune, LLC

A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
MedImmune, LLC

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma
MedImmune, LLC

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents
MedImmune, LLC

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
MedImmune, LLC

A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma
MedImmune, LLC

A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
MedImmune, LLC

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
MedImmune, LLC

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
MedImmune, LLC

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
MedImmune, LLC

A Double-masked, Placebo-controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
MedImmune, LLC

EVADE: A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa
MedImmune, LLC

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Institution: Information not provided - NL